Abko buys ~40% of US medical AI startup Bullseye to push into healthcare
What's the deal? AbkoDealroom has a profile for this one. Try Dealroom →, a South Korean electronics maker, has acquired roughly 40% of Bullseye BiodevicesDealroom has a profile for this one. Try Dealroom →, a US medical AI startup, becoming a major shareholder. It completed a new share subscription agreement and transferred the funds, the company said on July 21, 2026.
Who are the players? Founded in 2001, Abko develops and manufactures gaming gear — keyboards, mice, and headsets — plus small appliances and audio devices. Bullseye builds AI solutions based on medical data.
What's the endgame? Bullseye is developing sensors that mount on surgical robots to measure electrical, optical, and mechanical biosignals at surgical sites. The technology will first target cancer surgery — lung, liver, and colorectal — before expanding to regenerative medicine, cardiovascular disease, and degenerative disease.
Why now? Abko's performance rebounded in 2025 on high-value-added products, and it has been pursuing expansion through equity investments. It plans to combine Bullseye's medical AI with its own manufacturing expertise to enter the medical device market.
The company also envisions extending biosensing technology into smart healthcare and beauty.
"This equity acquisition has laid the groundwork for a cutting-edge medical AI business that will lead the global market," an Abko official said, adding it plans to "quickly deliver tangible results in the global medical and healthcare markets."
The signal: A consumer electronics manufacturer taking a controlling-adjacent stake in a medical AI firm reflects a wider push by hardware makers to diversify into higher-margin health tech, where sensing and AI converge on surgical precision.
Read more: The Korea Economic Daily
Image credit: NavyMedicine
